Cytokinetics plunges 19% after Phase 2 trial of ALS drug fails to meet endpoints [MarketWatch]
Cytokinetics, Incorporated (CYTK)
Last cytokinetics, incorporated earnings: 3/3 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytokinetics.com/investor-overview
Company Research
Source: MarketWatch
Cytokinetics plunges 19% after Phase 2 trial of ALS drug fails to meet endpoints Shares of biotech Cytokinetics Inc. CYTK, -3.50% plunged 19% in premarket trade Monday after the company announced that a Phase 2 study of its amyotrophic lateral sclerosis drug did not show a meaningful difference in respiratory function, muscle strength or daily living measures compared with placebo. After 12 weeks on the drug, called reldesemtiv, patients did not show a statistically-significant difference in symptoms at three different dosage points when compared with patients on a placebo, though a post-hoc analysis grouping all treatment groups together showed improvement in daily living compared with placebo. Shares of Cytokinetics have gained 40% in the year to date, while the S&P 500 SPX, -1.20% has gained 17.5%. Have breaking news sent to your inbox. Subscribe to MarketWatch's free Bulletin emails. Sign up here.
Show less
Read more
Impact Snapshot
Event Time:
CYTK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYTK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYTK alerts
High impacting Cytokinetics, Incorporated news events
Weekly update
A roundup of the hottest topics
CYTK
News
- Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target raised by analysts at Mizuho from $99.00 to $103.00. They now have an "outperform" rating on the stock.MarketBeat
- Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan [Yahoo! Finance]Yahoo! Finance
- Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $72.00 price target on the stock.MarketBeat
- Cytokinetics and Bayer partner to develop for aficamten in Japan [Seeking Alpha]Seeking Alpha
- Cytokinetics Will Get More Revenue for Marketing Aficamten in Japan [Yahoo! Finance]Yahoo! Finance
CYTK
Earnings
- 11/6/24 - Miss
CYTK
Sec Filings
- 11/19/24 - Form 4
- 11/19/24 - Form 8-K
- 11/18/24 - Form 144
- CYTK's page on the SEC website